A systematic review of the effectiveness of adalimumab

138
References
242. Winning A. Infliximab in the treatment of
rheumatoid arthritis. Journal of Clinical Excellence
2001;3:211–14.
243. Yung RL. Etanercept Immunex. Curr Opin Investig
Drugs 2001;2:216–21.
244. Anonymous. [Adalimumab slows the progression
of rheumatoid arthritis] [in German]. Pharm
Unserer Zeit 2003;32:75–6.
245. Anonymous. Etanercept/anakinra RA combination
therapy has increased risk compared to etanercept
monotherapy. Formulary 2004;39(8):394, 397.
246. Bain B, Brazil M. Adalimumab. Nat Rev Drug
Discov 2003;2(9):693–4.
247. Becker C. Adalimumab is suitable for everyday use
[in German]. Pharmazeutische Zeitung 2004;
149(26):28, 30.
248. Boers M, COBRA Study Group. Demonstration of
response in rheumatoid arthritis patients who are
nonresponders according to the American College
of Rheumatology 20% criteria: the paradox of
beneficial treatment effects in nonresponders in
the ATTRACT trial. Anti-Tumor Necrosis Factor
Trial in Rheumatoid Arthritis with Concomitant
Therapy. Arthritis Rheum 2001;44:2703–4.
249. Bruhn C. Adalimumab – the first pure human
monoclonal antibody for the treatment of
rheumatoid arthritis [in German]. Deutsche
Apotheker Zeitung 2002;142(45):38–40.
250. Bruhn C. Rheumatoid arthritis: combination of
etanercept and methotrexate is superior to
monotherapy [in German]. Deutsche Apotheker
Zeitung 2004;144(21):46–8.
251. Choy EH. Two is better than one? Combination
therapy in rheumatoid arthritis. Rheumatology
2004;43:1205–7.
252. Cutolo M. Etanercept improves rheumatoid
arthritis partially responsive to methotrexate. Clin
Exp Rheumatol 2001;19:626–7.
253. Czajka S. Long-term study on infliximab [in
German]. Pharmazeutische Zeitung 2001;146(16):30,
32.
254. Haneveld JK. Combination treatment with
etanercept and methotrexate for rheumatoid
arthritis [in Dutch]. Pharmaceutisch Weekblad 2004;
139:870–1.
255. Hellwig B. Rheumatoid arthritis: adalimumab –
new antibody against TNF alpha [in German].
Deutsche Apotheker Zeitung 2003;143(38):48–50.
256. Masche UP. Adalimumab [in German]. Pharma-
Kritik 2003;25(9):35–6.
257. Matucci-Cerinic M. The addition of adalimumab
to methotrexate reduces rheumatoid arthritis
activity in patients with longstanding disease. Clin
Exp Rheumatol 2004;22:34–5.
258. Moreland L. Infliximab in rheumatoid arthritis.
Curr Rheumatol Rep 2004;6:334–5.
259. Moreland L. Adalimumab in rheumatoid arthritis.
Curr Rheumatol Rep 2004;6:333–4.
260. Rothschild BM. American College of
Rheumatology – 65th Annual Meeting: TNF
therapies: 11–15 November 2001, San Francisco,
CA, USA. Idrugs 2002;5:35–7.
261. Braddock M. 2nd International Conference on
Immune-Mediated Diseases & 8th International
Anti-Inflammation Meeting. Expert Opin Investig
Drugs 2004;13:555–64.
262. Croasdell G. JP Morgan Hambrecht & Quist – 21st
Annual Healthcare Conference: 6–9 January 2003,
San Francisco, CA, USA. Idrugs 2003;6:93–6.
263. Evans R. Inflammation 2003 – Sixth World
Congress: 2–6 August 2003, Vancouver, Canada.
Idrugs 2003;6:831–3.
264. Levy RA, Galarza C, Shoenfeld Y. I Latin
American Congress of Autoimmunity Galapagos –
September 15–18. Autoimmunity Reviews 2004;
3:76–87.
265. Oelke K. American College of Rheumatology –
65th Annual Meeting: 10–15 November 2001,
San Francisco, CA, USA. Idrugs 2002;5:30–1.
266. Trepman E, Lutter LD, Thordarson DB, Greer RE,
Lutter J. Highlights of the Nineteenth Annual
Summer Meeting of the American Orthopaedic
Foot and Ankle Society, Hilton Head, South
Carolina, June 27–29, 2003. Foot and Ankle Surgery
2003;9:245–54.
267. Yung RL. American College of Rheumatology –
65th Annual Meeting Degenerative Joint Diseases
11–15 November 2001, San Francisco, CA, USA.
Idrugs 2002;5:32–4.
268. van de Putte L, Bergemann R, Rosery H, Pang F,
Dietz B, Kupper H, et al. Variation in resource
utilization and treatment costs for rheumatoid
arthritis (RA) across 5 countries in an adalimumab
(D2E7) clinical trial [abstract]. Value Health 2002;
5:475–6.